英派斯涨2.04%，成交额4587.41万元，主力资金净流入390.24万元

Core Viewpoint - The stock of Qingdao Inpace Health Technology Co., Ltd. has shown a significant increase in price and trading activity, indicating positive market sentiment despite a decline in revenue and net profit for the year [1][2]. Group 1: Stock Performance - On December 24, Inpace's stock rose by 2.04%, reaching 25.98 CNY per share, with a trading volume of 45.87 million CNY and a turnover rate of 1.22%, resulting in a total market capitalization of 3.84 billion CNY [1]. - Year-to-date, Inpace's stock price has increased by 16.26%, with a 7.58% rise over the last five trading days, 9.62% over the last 20 days, and 27.29% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on April 14 [1]. Group 2: Financial Performance - For the period from January to September 2025, Inpace reported a revenue of 856 million CNY, a year-on-year decrease of 4.53%, and a net profit attributable to shareholders of 50.75 million CNY, down 41.88% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 56.19 million CNY, with 28.95 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Inpace is 14,800, a decrease of 24.69% from the previous period, while the average number of circulating shares per person has increased by 32.78% to 10,016 shares [2]. - Among the top ten circulating shareholders, new entrants include Minsheng Jia Yin Continuous Growth Mixed A and Yin Hua Quality Consumption Stock A, with respective holdings of 1.36 million shares and 803,400 shares [3].